• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more


The latest news for pharma industry insiders.

LogiPharma Europe 2024: A Digital Capability Transformation

Panel discussion uncovers how to alter one’s digital know-how for use in temperature-controlled supply chain.

Talking About the Generations: The Health and Healthcare of Boomers, Gen Xers, Millennials and Gen Zers. Part 3, Millennials

Millennials (1981–1996), burdened by health problems and costly

Certain Biotech Investors Get an Early Look at Results. Is That Fair?

Private investments in public equities, or PIPEs, are all the rage in biotech, but some investors resent the sharing of nonpublic information.

DoseMe Expands Global Footprint as Premier Hospitals and Cancer Centers across Australia Continue to Adopt Bayesian Dosing

Healthcare organizations utilizing DoseMeRx are experiencing improved patient outcomes and hospital economic health.

Enveric Biosciences, Inc. on LinkedIn:

Last month Enveric Biosciences, Inc. CEO Joseph Tucker, PhD, spoke with Pharmaceutical Executive about the growing #NonHallucinogenic #Psychedelic Pipeline.

Read about it here. https://lnkd.in/eYE9SRUX

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs